Mosquito- and tickborne diseases are a growing threat in every US state and territory. At Evolva we'll continue to develop new solutions that address customer and consumers' needs around the world and can contribute to health and wellbeing" said Oliver Walker, CEO of Evolva. "NootkaShield™ is another example of our innovative power. Evolva has a long-standing commitment to advancing research across a broad range of areas that accelerate the development of ingredients based on nature. In 2017, Evolva received a contract from the Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to develop a next-generation active ingredient for use in insecticides and insect repellents to protect people. In 2014 Evolva started to work with the support of the US Centers for Disease Control and Prevention (CDC), the nation's health protection agency, on research and development of nootkatone. Evolva as well as companies interested in developing their own consumer products will be required to submit a registration package (efficacy, safety and product characterization) to EPA for review, and products could be commercially available as early as 2022. In line with this, we are also investing in the development and registration of own formulations. Evolva is in discussion with a growing number of pest control companies to plan commercial next steps in order to expedite the development and marketing of new consumer products. Nootkatone can now be used to develop new insect repellents and insecticides for protecting people. Reinach, AugEvolva, the Swiss biotech company, announced today that NootkaShield™ (branded nootkatone), for use in insecticides and insect repellents, is now registered as an active ingredient with the US Environmental Protection Agency (EPA).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |